Immunotherapy shows promise in extending control of resistant ovarian cancer
NCT ID NCT03430700
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study tested whether the immunotherapy drug pembrolizumab could help keep ovarian cancer from growing after initial chemotherapy. Twenty women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer received weekly paclitaxel followed by pembrolizumab as maintenance therapy. The goal was to see if more than 16 out of 20 participants remained cancer-free for at least 6 months. The trial also studied how the immune system changes during treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts
London, United Kingdom
-
Churchill Hospital
Oxford, United Kingdom
-
Imperial
London, United Kingdom
-
UCLH
London, United Kingdom
Conditions
Explore the condition pages connected to this study.